Progenics Pharmaceuticals, Inc. has entered an agreement with the Centre for Probe Development and Commercialization (CPDC) for the manufacture of Azedra, a targeted radiotherapy candidate in Phase II trials in patients with pheochromocytoma and paraganglioma.
"CPDC, and their host, McMaster University, serve as a model of how collaborative efforts can advance medical discoveries to commercialization," said Mark Baker, chief executive officer of Progenics. "We believe CPDC has the proven ability to meet our demanding standards and timelines, in tandem with the ingenuity and flexibility necessary to manufacture small batches of radiopharmaceuticals in a cost-effective manner. We look forward to a strong partnership with CPDC as this, and our other radiotherapeutic programs develop."
Dr. John Valliant, chief executive officer and scientific director of CPDC, said, "Our industry expertise and manufacturing capabilities, the skilled support staff and world-class facilities available to us at McMaster University and the support of the Canadian Government, make us uniquely qualified to collaborate with companies like Progenics. We believe this partnership between two innovative industry leaders will play a pivotal role in advancing new technologies for the treatment of cancers."